Therefore, we treated breast cancer cell lines with different concentrations of the CREBBP inhibitor C646 and found that the expression level of NUCB2 decreased in a dose-dependent manner with increasing concentrations of C646, suggesting that NUCB2 may be overexpressed in breast cancer cells potentially through protein acetylation. This evidence concerns the gene CREBBP and breast carcinoma.